Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Healthcare Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Sirona Biochem Corp > @PRC - Potential TFC-1067 - year 1-5
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(77)
•••
Comment by Pareto8020on Jun 26, 2022 1:07pm
162 Views
Post# 34783138

RE:RE:RE:@PRC - Potential TFC-1067 - year 1-5

RE:RE:RE:@PRC - Potential TFC-1067 - year 1-5

That's why the Allergan deal details matter and need to be released to unlock SBM's value.

If the upfront isn't very large then there won't be any pressure on Allergan to get to market quickly to start making a return on their investment.  Details matter to the investment community.

 I get the impression it is a fairly substantial deal given all the promised upcoming action - but once again Howard leaves everyone guessing and scratching their heads so nobody is piling into this play with so many unknowns.  I'd bet the share price would be more than a dollar if some of the financial metrics of the deal were released.  Part time CEO yields part time results.
 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities